Welcome to our dedicated page for Marker Therapeut news (Ticker: MRKR), a resource for investors and traders seeking the latest updates and insights on Marker Therapeut stock.
Marker Therapeutics, Inc. (Nasdaq: MRKR) is a Houston, Texas-based, clinical-stage immuno-oncology company developing multi-antigen recognizing T cell (MAR-T) therapies for hematological malignancies and solid tumors. This news page aggregates company press releases and third-party coverage related to MRKR, with a focus on clinical data, research milestones, and corporate developments.
Investors and followers of MRKR can review updates on the company’s lead program, MT-601, a MAR-T cell product being evaluated in the Phase 1 APOLLO trial for patients with relapsed or refractory lymphoma who have failed or are not candidates for anti-CD19 CAR-T cell therapy. News items include reported objective response rates, safety findings such as the absence of dose-limiting toxicities and ICANS in dose escalation cohorts, and progress into dose expansion in diffuse large B cell lymphoma.
Coverage also highlights Marker’s expansion into additional indications, including a pancreatic cancer program supported by non-dilutive funding and an Off-the-Shelf MAR-T initiative, MT-401-OTS, in the RAPID trial for relapsed acute myeloid leukemia or myelodysplastic syndromes. Readers will find announcements on first-patient dosing, early safety observations, and scientific insights such as the impact of lymphodepletion on MAR-T cell expansion and persistence.
Beyond clinical results, MRKR news includes financial updates, grant awards from U.S. state and federal agencies, collaborations such as the cGMP manufacturing agreement with Cellipont Bioservices for MT-601, participation in investor conferences, and changes in corporate governance and auditors. This page is a resource for tracking how Marker’s MAR-T platform and pipeline evolve over time.
Marker Therapeutics (Nasdaq: MRKR) announced that the FDA has lifted the partial clinical hold on its Phase 2 trial for MT-401, a T cell therapy aimed at treating post-transplant acute myeloid leukemia (AML). This decision allows for the continued enrollment of patients in the trial, which evaluates MT-401's safety and efficacy compared to standard care. The trial, which includes approximately 120 patients in the adjuvant setting and 40 with active disease, aims to assess various survival metrics and remission rates. MT-401 has previously received Orphan Drug designation from the FDA.
Marker Therapeutics, Inc. (Nasdaq:MRKR) reported significant progress in its Phase 2 trial of MT-401 for acute myeloid leukemia (AML) in Q3 2020. The company enrolled its first patient for the safety lead-in portion and plans to activate approximately 20 clinical sites. Manufacturing improvements resulted in a 50% reduction in production time. Financially, Marker had cash and equivalents of $27.0 million, with a net loss of $7.4 million for the quarter, up from $5.5 million in Q3 2019. The new cGMP facility is on track for completion by year-end.
Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company, will host a conference call on November 9, 2020, at 5:00 p.m. Eastern Time to discuss its third quarter 2020 financial and operating results. The call will be accessible via the company’s website, and a replay will be available afterwards. Marker Therapeutics focuses on developing next-generation T cell-based immunotherapies for hematological and solid tumors, utilizing non-engineered, tumor-specific T cells to target multiple tumor antigens.
Marker Therapeutics (NASDAQ:MRKR), a leader in immuno-oncology, announced that CEO Peter L. Hoang will present at the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020, from 1:40 to 2:20 p.m. ET. The event will showcase the company's innovative T cell-based therapies targeting hematological malignancies and solid tumors. Live webcasts of the presentation will be available on the Investors section of their website and can be replayed afterward.
Marker Therapeutics (Nasdaq:MRKR) provided a corporate update and reported financial results for Q2 2020. The company continues to advance its Phase 2 trial for MultiTAA-specific T cell therapy targeting acute myeloid leukemia (AML) despite COVID-19 challenges. Marker has cash reserves of $32.1 million, expected to fund operations into Q2 2021. R&D expenses rose to $4.3 million, while general and administrative costs decreased to $2.5 million. The net loss for the quarter was $6.3 million, compared to $5.6 million in Q2 2019.
Marker Therapeutics (MRKR) has announced a new lease agreement for a cGMP manufacturing facility in Houston, TX, expected to be operational by 2021. This facility will enhance the company's capacity to produce its MultiTAA-specific T cell therapies according to FDA standards, enabling clinical trials for hematological malignancies and solid tumors. The facility spans approximately 48,500 square feet and reinforces Marker’s strategic plans as it advances its AML trial. The company continues to manufacture its therapies at Baylor College of Medicine until the new facility is operational.
Marker Therapeutics, Inc. (Nasdaq: MRKR) announced that the USAN Council has approved "zelenoleucel" as the generic name for MT-401, a T cell therapy targeting acute myeloid leukemia (AML) after stem cell transplants. The therapy, which received Orphan Drug designation in April, has shown clinical benefits in trials. CEO Peter L. Hoang highlighted the significance of this approval as it marks progress in their clinical development and anticipates starting a Phase 2 study for AML patients.